KZR-616-208
Brief description of study
To evaluate the safety and tolerability of zetomipzomib in patients with autoimmune hepatitis (AIH) and to evaluate the efficacy of the drug in addition to standard-of-care in patients with AIH who have failed standard-of-care treatment. Target population = 3 subjects. Subjects will be randomized to either treatment or control and be on drug for 28 weeks. Study procedures include labs, physical examination, vitals, ECG, surveys, fibroscan, liver biopsies, and drug administration.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
